New antibody shot could help protect babies from RSV
A newly approved shot could soon help protect babies from respiratory syncytial virus (RSV), the top cause of hospitalization in U.S. infants.
Jun 12, 2025
0
17
MeSH tree: C01.748.099.135
A newly approved shot could soon help protect babies from respiratory syncytial virus (RSV), the top cause of hospitalization in U.S. infants.
Jun 12, 2025
0
17
As winter settles over Australia, it's not just the drop in temperature we notice—there's also a sharp rise in respiratory illnesses. Most of us are familiar with the usual winter players such as COVID, influenza and RSV ...
Jun 10, 2025
0
14
A single dose of the long-acting antibody nirsevimab to infants can halve hospitalizations for bronchiolitis.
Jun 3, 2025
0
21
An Australian-first study demonstrating the effectiveness of a new immunization against respiratory syncytial virus (RSV) for babies found it to be almost 90% effective in reducing hospitalization rates and helped more than ...
Mar 28, 2025
0
19
Respiratory syncytial virus, or RSV, is something many parents know as a cause of bronchiolitis, but others may not have heard of it until recently. RSV causes infections of the lungs and respiratory tract. It's common in ...
Nov 19, 2024
0
47
Respiratory syncytial virus (RSV) remains the top cause of hospitalization among young children, leading to respiratory issues like bronchiolitis and pneumonia. However, the reasons why some children experience only mild ...
Oct 12, 2024
0
67
For infants and young children hospitalized with respiratory syncytial virus (RSV) infection, ziresovir reduces signs and symptoms of bronchiolitis, according to a study published in the Sept. 26 issue of the New England ...
Sep 27, 2024
0
27
As winter rolls on in Australia, respiratory viruses are everywhere. One of the main culprits is respiratory syncytial virus, or RSV, which has caused more than 145,000 infections around the country so far this year. Most ...
Aug 27, 2024
0
24
Scientists have discovered how the dangerous respiratory syncytial virus (RSV) defuses our immune response and, in doing so, have pinpointed an exciting new target for drug developers.
Jul 18, 2024
0
46
A study conducted in Brazil points to long-term functional abnormalities in their lungs two years after hospital discharge in most severe COVID-19 patients who had required intubation, and a return of pulmonary lesions after ...
Jul 10, 2024
0
34